Crossmark

281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0281

Published Online: 2020-11-09

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Galffy, Gabriella

Lugowska, Iwona

Poddubskaya, Elena

Cho, Byoung Chul

Ahn, Myung-Ju

Han, Ji-Youn

Su, Wu-Chou

Hauke, Ralph

Dyar, Stephen

Lee, Dae Ho

Serwatowski, Piotr

Estelles, David Lorente

Holden, Viran

Kim, Yu Jung

Vladimirov, Vladimir

Horvath, Zsolt

Ghose, Abhimanyu

Goldman, Allison

Pietro, Alessandra di

Wang, Jing

Murphy, Danielle

Laskov, Mikhail
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03472560 at ClinicalTrials.gov

Documents that mention this clinical trial

281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC)
https://doi.org/10.1136/jitc-2020-sitc2020.0281
License Information

License valid from 2020-12-09

Document is current

Any future updates will be listed below